Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2025 08:50 ET | Source: Entera Bio

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

Consistency of BMD gains presented at NAMS 2025 demonstrate EB613’s efficacy in both young postmenopausal women and in women 10 years post-menopause Data further support EB613 potential as a...
October 16, 2025 08:45 ET | Source: Entera Bio

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

JERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new...
September 15, 2025 09:00 ET | Source: Entera Bio

Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress

Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 Therapy Oral GLP-2 Tablet Could Transform...
August 15, 2019 07:00 ET | Source: Entera Bio

Entera Bio to Announce Second Quarter and Six Months ended June 30, 2019 Financial Results on Tuesday, August 20, 2019

JERUSALEM, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the second quarter and six months ended June 30, 2019 before...
August 05, 2019 08:00 ET | Source: Entera Bio

Entera Bio Appoints Adam Gridley as Chief Executive Officer

JERUSALEM, Israel, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the appointment of Adam Gridley as Chief Executive Officer, effective immediately. Phillip...
July 02, 2019 07:00 ET | Source: Entera Bio

Entera Announces Initiation of Phase 2 Dose Ranging Study for Oral PTH

JERUSALEM, July 02, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it has initiated a Phase 2 study with its osteoporosis drug candidate EB613, an oral human PTH...
June 27, 2019 07:00 ET | Source: Entera Bio

Entera Bio Reports First Quarter 2019 Financial Results and Operating Update

Phase 2b Study for oral PTH in osteoporosis to begin by mid-year 2019Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Data processing and statistical analysis are ongoing,...
March 28, 2019 07:00 ET | Source: Entera Bio

Entera Bio Announces 20-F Filing

JERUSALEM, March 28, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2018, with the U.S....
March 28, 2019 07:00 ET | Source: Entera Bio

Entera Bio Reports 2018 Annual Financial Results and Operating Update

Positive feedback and guidance from the US FDA regarding development plans for Oral PTH in osteoporosisEntered into research collaboration and license agreement with Amgen, potential for up to $270...
March 27, 2019 11:02 ET | Source: Entera Bio

Entera Bio to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Thursday, March 28

JERUSALEM, March 27, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the fourth quarter and year ended December 31, 2018 before the...